| Uncoupling GP1 and GP2 Expression in the Lassa Virus Glycoprotein Complex: Implications for GPI Ectodomain Shedding |
23-Dec-2008 |
18 pages |
| Authors:
Luis M Branco; Alex Matschiner; Joseph N Fair; Megan M Illick; Kerry A Illick; Randal Schoepp; Robert F Garry; Mary C Guttieri; ARMY MEDICAL RESEARCH INST OF INFECTIOUS DISEASES FORT DETRICK MD
|
 | Bacillus anthracis lethal toxin (LT) was characterized in plasma from infected African Green monkeys, rabbits, and guinea pigs. In all cases, during the terminal phase of infection only the protease-activated 63-kDa form of protective antigen (PA63) and the residual 20-kDa fragment (PA20) were detected in the plasma. No uncut PA with a molecular mass of 83 kDa was detected in plasma from toxemic animals during the terminal stage of infection. ... |
|
| Uncoupling GP1 and GP2 Expression in the Lassa Virus Glycoprotein Complex: Implications for GP1 Ectodomain Shedding |
23-Dec-2008 |
19 pages |
| Authors:
Luis M Branco; Alex Matschiner; Joseph N Fair; Megan M Illick; Kerry A Illick; Randal Schoepp; Robert F Garry; Mary C Guttieri; BIOFACTURA INC ROCKVILLE MD
|
| Background: Sera from convalescent Lassa fever patients often contains antibodies to Lassa virus (LASV) glycoprotein 1 (GP1), and glycoprotein 2 (GP2); Immunization of non-human primates with viral vectors expressing the arenaviral glycoprotein complex (GPC) confers full protective immunity against a lethal challenge with LASV. Thus, the development of native or quasi native recombinant LASV GP1 and GP2 as soluble, uncoupled proteins will improve current diagnostics, treatment, and prevention of Lassa ... |
|
| Bacterial-based Systems for Expression and Purification of Recombinant Lassa Virus Proteins of Immunological Relevance |
06-Jun-2008 |
15 pages |
| Authors:
Luis M Branco; Robert B Tesh; Randal J Schoepp; Kathleen A Cashman; Philip J Ferro; Darryl B Sampey; Augustine Goba; Joseph N Fair; Alex Matschiner; Daniel G Bausch; ARMY MEDICAL RESEARCH INST OF INFECTIOUS DISEASES FORT DETRICK MD
|
| BACKGROUND: There is a significant requirement for the development and acquisition of reagents that will facilitate effective diagnosis, treatment, and prevention of Lassa fever. In this regard, recombinant Lassa virus (LASV) proteins may serve as valuable tools in diverse antiviral applications. Bacterial-based systems were engineered for expression and purification of recombinant LASV nucleoprotein (NP), glycoprotein 1 (GP1), and glycoprotein 2 (GP2). RESULTS: Full-length NP and the ectodomains of GP1 and ... |
|
Reports by Author
